

Intra-Cellular Therapies Inc. Investor Relations Department 430 East 29th Street Suite 900 New York, NY 10016 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: ITCI Last Trade: 15.96 Trade Time: 3:40 PM ET Oct 19, 2017 Change: -0.03 ♣ (-0.188%) Day Range 15.67 - 16.12 52-Week Range 7.85 - 22.67 Volume 278,301

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders.

ITI-007 is in Phase 3 clinical trials as a first-in-class t... (more)

Stock Performance



Press Releases [View all]

Oct 5, 2017

Intra-Cellular Therapies Announces Full
Exercise of Underwriters' Option to Purchase
Additional Shares of Common Stock

Oct 3, 2017

Intra-Cellular Therapies Announces

Commencement of Enrollment of a Clinical

Trial Evaluating ITI-214 in Patients with

Parkinson's Disease

Oct 2, 2017

Intra-Cellular Therapies Announces Closing of \$150 Million Public Offering of Common Stock

Sep 27, 2017

Intra-Cellular Therapies Prices \$150 Million
Public Offering of Common Stock

Sep 26, 2017

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

Financials [View all]

Second Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

May 1, 2017

Proxy Statement (DEF 14A)

Aua 9, 2017

Quarterly Report (10-Q)

May 10, 2017

Quarterly Report (10-Q)

Nov 9, 2016

Quarterly Report (10-Q)